Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Viread

(tenofovir)

PreclinicalSmall molecule

Tenofovir is used to treat HIV infection and chronic hepatitis B by helping to reduce the amount of virus in the body. It is an antiviral medication that helps prevent the virus from multiplying and damaging the immune system.[1] Viread is currently being investigated across 2 indications[3], with its most advanced program in Preclinical.[1]

Viread is one of 24 small molecule programs targeting Chronic Liver Failure. It is currently in Preclinical.

2

Indications

93

Total Trials

1

Active Trials

23

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Liver FailureActive, not recruiting

MonotherapyUnknown status

Chronic Liver FailurePreclinical

Active, not recruiting

MonotherapyPreclinical

Unknown status

Competition

Competitive Landscape

17 competitors in Monotherapy

#DrugCompanyPhaseTrials

Reblozyl

Bristol-Myers Squibb

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Opdivo

Bristol-Myers Squibb

Lenvima

Stivarga

Venclexta

Yervoy

Bristol-Myers Squibb

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Trifluridine/tipiracil

RP1

RReplimune Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Hepatitis23 trials

Randomized Controlled Study of Tenofovir Plus Telbivudine Versus Monotherapy With Either Drug in HBeAg Negative Chronic Hepatitis B Patients

Withdrawn·IInstitute of Liver and Biliary Sciences, India·N/A·NCT01260610

A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both

Completed· Roche logo

Roche·Phase 1·NCT00962871·30 enrolled

Simvastatin for the Treatment of Chronic Hepatitis B

Completed·—·Phase 1·NCT00994773·32 enrolled

Show 20 more trials

Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

Terminated· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 2·NCT02452528·4 enrolled

A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection

Terminated· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 2·NCT02604199·58 enrolled

From Fungus to Virus, Investigating the Safety and Efficacy of Terbinafine in Chronic Hepatitis B Patients

Recruiting·—·Phase 1/2·NCT06295328·36 enrolled

Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B

Completed·—·Phase 4·NCT01639066·102 enrolled

A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D

Completed·HHepatera Ltd.·Phase 2·NCT03546621·120 enrolled

Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00410202·629 enrolled

Tenofovir Disoproxil Fumarate vs. Entecavir in Chronic Hepatitis B Patients With Partial Virologic Response to Entecavir

Completed·KKorea University·Phase 4·NCT01711567·60 enrolled

Tenofovir Versus Lamivudine for Patients of Chronic Hepatitis B With Severe Acute Exacerbation

Unknown status·KKaohsiung Veterans General Hospital.·Phase 3·NCT01848743·120 enrolled

A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)

Completed· Novartis logo

Novartis·Phase 4·NCT00651209·105 enrolled

Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues

Completed· IlDong Pharmaceutical Co Ltd logo

IlDong Pharmaceutical Co Ltd·Phase 3·NCT02792088·146 enrolled

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01525628·72 enrolled

A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 4·NCT01727271

A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.

Completed· Roche logo

Roche·Phase 3·NCT01088659·50 enrolled

Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection

Terminated· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 2·NCT02738008·12 enrolled

A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection

Completed· Roche logo

Roche·Phase 2·NCT02391805·31 enrolled

Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01063036·144 enrolled

Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT01369212·201 enrolled

A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)

Terminated· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 1·NCT02797522·47 enrolled

Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B

Terminated·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00524173·35 enrolled

Tenofovir vs. Tenofovir Plus Entecavir in Entecavir-Resistant Chronic Hepatitis B

Completed·—·Phase 4·NCT01639092·88 enrolled

Tenofovir16 trials

Role of Exogenous and Endogenous Sex Hormones on Tenofovir and Emtricitabine Disposition in Female Genital Tract

Completed·UUniversity of Minnesota··NCT03218085·28 enrolled

A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants

Completed·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT02039323·6 enrolled

Antiretroviral Switch From Didanosine to Tenofovir in HIV/HCV Co-infected Patients

Completed·UUniversity of British Columbia·Phase 4·NCT00358696·30 enrolled

Show 13 more trials

Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression

Completed·UUniversity of Maryland, Baltimore·N/A·NCT00344981·9 enrolled

Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir

Unknown status·PPusan National University Yangsan Hospital·Phase 4·NCT01588912·104 enrolled

Interventional Study of Mucosal and Antimicrobial Responses to Repeated Vaginal Applications of Tenofovir Gel in HIV Uninfected Women

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00594373·30 enrolled

Simple Once Daily Triple Regimen Including Tenofovir, Emtricitabine and Efavirenz in HIV-1 Infected Patients (ANRS 1207)

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00158457·40 enrolled

Tenofovir/Emtricitabine for PMTCT in Africa and Asia (ANRS 12109 TEmAA)

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00334256·72 enrolled

Tenofovir Abacavir Platelet Activation Study

Completed·JJan Gerstoft·Phase 4·NCT02093585·43 enrolled

Comparison of Tenofovir Vaginal Gel and Film Formulations

Completed·CCONRAD·Phase 1·NCT02280109·10 enrolled

Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel

Completed·CCONRAD·Phase 1·NCT00561496·49 enrolled

Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir

Completed·UUniversity of California, San Diego·Phase 2·NCT00214890·21 enrolled

Comparative Safety Study of Two Vaginal Applicators With Tenofovir

Completed·PPATH·N/A·NCT01283555·25 enrolled

Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC

Completed·GGuangxi Medical University·Phase 3·NCT02650271·240 enrolled

Differences Between Stavudine and Tenofovir Each Combined With Lamivudine and Efavirenz in SA HIV-infected Patients

Terminated·UUniversity of Witwatersrand, South Africa·Phase 4·NCT01601899·60 enrolled

Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy

Completed·SShanghai Public Health Clinical Center·Phase 4·NCT02945163·184 enrolled

Hepatitis B7 trials

To Compare the Efficacy of Combined Tenofovir Plus Telbivudine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT01732224·69 enrolled

Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent

Completed·HHepatera Ltd.·Phase 2·NCT02888106·90 enrolled

TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA

Completed·KKeimyung University Dongsan Medical Center·Phase 4·NCT01732367·171 enrolled

Show 4 more trials

Using Flavonoids to Kill Hepatitis B Virus

Completed·TTrieu, Nguyen Thi, M.D.·Phase 4·NCT07084948·134 enrolled

Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity

Unknown status·OOttawa Hospital Research Institute·Phase 3·NCT03759782·24 enrolled

Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB

Completed· Novartis logo

Novartis·Phase 3·NCT00805675·83 enrolled

Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection

Completed·IInternational Antiviral Therapy Evaluation Center·Phase 4·NCT00127959·24 enrolled

HIV infection4 trials

Study to Evaluate a HIV Drug for the Treatment of HIV Infection

Completed· GSK logo

GSK·Phase 2·NCT01803074·107 enrolled

Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 4·NCT01232127·25 enrolled

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

Completed·KKirby Institute·Phase 4·NCT00192660·80 enrolled

Show 1 more trial

Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection

Completed·SSEARCH Research Foundation·Phase 1/2·NCT02475915·15 enrolled

Efficacy3 trials

The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age

Completed·IImperial College London·Phase 4·NCT01335620·19 enrolled

A Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic HBV

Completed·FF-star Therapeutics, Inc.·Phase 2·NCT02751996·80 enrolled

Efficacy of HBV Vaccine in Consolidation of Nucleos(t)Ide Analogues Therapy

Completed·—·Phase 4·NCT02505009·116 enrolled

29 more indications

Acceptability3 trials

Safety and Acceptability of the Anti-Microbe Vaginal Gel, PMPA Gel

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00028132·120 enrolled

Adherence and Acceptability to and Blood Levels of Tenofovir Gel and Tablets in HIV Uninfected Women

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00592124·168 enrolled

Rectal Microbicide Safety and Acceptability Trial of Topically Applied Tenofovir Compared With Oral Tablet

Completed·CCONRAD·Phase 1·NCT00984971·18 enrolled

Immunodeficiency3 trials

Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00350272·76 enrolled

HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

Completed· GSK logo

GSK·Phase 2·NCT01384734·254 enrolled

Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection

Completed·CCONRAD·Phase 3·NCT01386294·2,059 enrolled

Pregnancy2 trials

The Effect of Anti-viral Drugs Used in Late Pregnancy on Long-term Development of Children

Unknown status·—··NCT02301650·400 enrolled

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)··NCT00042289·1,578 enrolled

Lymphoma2 trials

Entecavir and Tenofovir Versus Entecavir in Lymphoma Patients With Positive HBV DNA

Unknown status·RRuijin Hospital·Phase 3·NCT04539119·120 enrolled

To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma

Unknown status·SSeoul National University Hospital·Phase 4·NCT02585947·90 enrolled

Adolescent2 trials

The CHAPS Trial: Combined HIV Adolescent PrEP and Prevention

Completed·WWits Health Consortium (Pty) Ltd·Phase 2·NCT03986970·72 enrolled

IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

Completed·IInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group··NCT00977756·168 enrolled

CLE2 trials

Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract

Completed·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT03917420·10 enrolled

Nucleosides And Darunavir/Dolutegravir In Africa

Unknown status·MMakerere University·Phase 3·NCT03988452·465 enrolled

Drug2 trials

A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy

Completed· GSK logo

GSK·Phase 3·NCT00053638·345 enrolled

Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure

Completed· GSK logo

GSK·Phase 4·NCT00038506·100 enrolled

Single Dose1 trial

Single Dose Truvada Study

Completed·JJohns Hopkins University·Phase 1·NCT03719053·44 enrolled

Hepatocellular Carcinoma1 trial

Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma

Terminated·TTaichung Veterans General Hospital·Phase 3·NCT01872988·320 enrolled

Medication1 trial

Effect on HIV Medications on EPC Cells

Completed·SSabyasachi Sen··NCT03782142·22 enrolled

Children1 trial

Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children

Completed·TThe HIV Netherlands Australia Thailand Research Collaboration··NCT01225406·56 enrolled

HIV1 trial

A Study of PMPA in HIV-Infected Patients

Completed· Gilead logo

Gilead·Phase 1·NCT00002180

Chronic Hepatitis B Virus Infection1 trial

A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection

Terminated· Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals·Phase 2·NCT02604212·32 enrolled

Immune1 trial

TDF and LdT in Immune-tolerant CHB Patients Awaiting Assisted Reproduction

Completed·FFuzhou General Hospital·Phase 1/2·NCT02338674·121 enrolled

Quality of Life1 trial

Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy

Completed·TTufts University·Phase 4·NCT01694017·68 enrolled

Combination Therapy1 trial

Trial of Telbivudine Combination Therapy vs. Continued Adefovir Monotherapy

Withdrawn· Novartis logo

Novartis·Phase 4·NCT00409019

Efficacy and Safety1 trial

Efficacy and Safety of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir in HIV-Infected Patients

Terminated·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00122577·50 enrolled

Effectiveness1 trial

Safety and Effectiveness Study of a Candidate Vaginal Microbicide for Prevention of HIV

Completed·CCentre for the AIDS Programme of Research in South Africa·Phase 2·NCT00441298·889 enrolled

Treatment1 trial

Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

Terminated· GSK logo

GSK·Phase 2·NCT02386098·86 enrolled

Tenofovir Disoproxil Fumarate1 trial

A Drug-Drug Interaction Study Between ATI-2173 and Tenofovir Disoproxil Fumarate in Healthy Subjects

Completed·AAntios Therapeutics, Inc·Phase 1·NCT05137548·32 enrolled

HIV-1 infection1 trial

Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01489046·297 enrolled

Menstrual Cycle1 trial

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women

Completed·UUniversity of Alabama at Birmingham·Phase 4·NCT00869960·24 enrolled

Chronic Liver Failure1 trial

Randomized Controlled Trial Comparing the Efficacy and Safety of FMT in Hepatitis B Reactivation Leads to Acute on Chronic Liver Failure.

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02689245·64 enrolled

HBV Coinfection1 trial

Tenofovir in HIV/HBV Coinfection

Completed·KKirby Institute·Phase 4·NCT00192595·36 enrolled

Impaired Renal Function1 trial

Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT02116660·11 enrolled

Cirrhosis1 trial

A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis

Unknown status·—·Phase 4·NCT02238860·100 enrolled

Monotherapy1 trial

Efficacy of Addition of Fecal Microbiota Transplant (FMT) and Plasma Exchange to Tenofovir in Comparison to Monotherapy With Tenofovir in ACLF-HBV

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT04431375·70 enrolled

HIV-11 trial

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

Completed· GSK logo

GSK·Phase 3·NCT00044577·166 enrolled

Unspecified3 trials

Test Albuvirtide in Experienced Patients

Completed·FFrontier Biotechnologies Inc.·Phase 3·NCT02369965·418 enrolled

TDF Long Term Study

Completed·TThe HIV Netherlands Australia Thailand Research Collaboration··NCT01815255·36 enrolled

Phase 3 and Extensional Study of Besifovir

Unknown status· IlDong Pharmaceutical Co Ltd logo

IlDong Pharmaceutical Co Ltd·Phase 3·NCT01937806·197 enrolled

Sources

References

[1]
ClinicalTrials.gov — 93 trial records for tenofovir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — tenofovir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for tenofovir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GSK

Related News